Dual-diagnosis treatment: integrated care for SMI and SUD

For decades, mental health and addiction services in most countries existed in parallel universes. People with both conditions got bounced between them — told by the addiction clinic to "get your psychiatric symptoms under control first" and by the psychiatric clinic to "get sober before we can really help you." The result was predictable: poor engagement, repeated hospitalisations, and worse outcomes than either condition alone would have produced. Over the last 30 years, a growing body of research has established that integrated treatment — a single team treating both conditions simultaneously — produces dramatically better outcomes. This article explains the evidence, the model, and how to find integrated care if it isn't obvious in your area.

How common is dual diagnosis?

The Epidemiologic Catchment Area study estimated that 47 percent of people with schizophrenia met lifetime criteria for a substance use disorder, compared with around 17 percent of the general population. The 2022 National Survey on Drug Use and Health from SAMHSA found that 21.5 million US adults had co-occurring serious mental illness and substance use disorder. Within schizophrenia specifically:

• Tobacco use disorder — 50 to 70 percent
• Alcohol use disorder — 20 to 35 percent
• Cannabis use disorder — 15 to 25 percent
• Stimulant use disorder — 10 to 15 percent
• Opioid use disorder — 5 to 12 percent

Why integrated care matters

The seminal work on integrated dual disorder treatment (IDDT) came out of the New Hampshire-Dartmouth Psychiatric Research Center in the 1980s and 1990s, led by Drake, Mueser, and others. Their longitudinal studies and several subsequent randomised trials demonstrated that integrated treatment produced:

• Higher rates of substance abstinence at 1, 3, and 5 years
• Lower rates of psychiatric rehospitalisation
• Better quality of life
• Higher rates of independent living and employment
• Lower mortality

The reasons are straightforward. Substance use directly affects psychiatric symptoms and medication response. Psychiatric symptoms drive substance use. Treatment cannot meaningfully separate them.

What "integrated" actually means

The IDDT model has several specific features beyond just "we treat both":

1. One team, one plan

The same clinicians address both psychiatric and substance use issues at every visit, rather than handing off between specialists.

2. Stage-wise treatment

Care matches the person's current readiness to change, using stages like engagement, persuasion, active treatment, and relapse prevention. Pushing someone in pre-contemplation toward abstinence-focused treatment usually fails; meeting them where they are works.

3. Motivational interviewing

A non-confrontational style that elicits the person's own reasons for change rather than lecturing about consequences. See our article on MI in schizophrenia.

4. Long-term perspective

IDDT assumes recovery takes years, not weeks. Repeated lapses are part of the process and not grounds for discharge.

5. Comprehensive scope

Beyond medication and counselling: housing support, vocational rehabilitation, family education, peer support, and case management.

6. Assertive outreach

The team goes to where people are — homes, shelters, streets — rather than waiting for missed appointments. Often delivered through assertive community treatment teams.

7. Harm reduction integrated with abstinence

Recognising that any reduction in use produces benefit; that complete abstinence is a worthy goal but not the only useful one. See our article on harm reduction.

The evidence base

SAMHSA designates IDDT as an evidence-based practice. The model is summarised in the SAMHSA disorders portal and detailed in implementation toolkits. Key trials include Drake et al.'s 7-year follow-up of the New Hampshire dual-diagnosis study, which found substantially better substance and psychiatric outcomes in integrated treatment. The model has been replicated in the UK, Netherlands, Germany, Canada, and Australia.

What integrated treatment looks like in practice

A typical IDDT-style program might include:

• A team of 6 to 12 clinicians (psychiatrist, nurses, social workers, addiction counsellors, peer support workers, vocational specialist) with a shared caseload
• Weekly team meetings to coordinate care across all clients
• Home and community visits, not just clinic appointments
• Co-located substance use groups and psychiatric services
• Medication for both conditions — antipsychotics plus, where appropriate, naltrexone, acamprosate, buprenorphine, or varenicline
• Family education and involvement
• Long-term enrolment, typically years

How to find integrated care

If you're not sure whether your local services are integrated, ask:

• "Do you have a dual diagnosis program or co-occurring disorders track?"
• "Will the same clinician treat my psychiatric symptoms and my substance use?"
• "Will I be discharged if I relapse on substances?"
• "Do you prescribe medication for opioid use disorder or alcohol use disorder?"

If the answers are no, look for:

• A community mental health centre with an integrated dual diagnosis program (often funded by SAMHSA grants)
• An assertive community treatment (ACT) team — most are now integrated
• A coordinated specialty care (CSC) program if you're early in the illness — see our CSC article
• SAMHSA's Find Treatment tool

What if you can't access full IDDT?

Many people live in areas without true integrated programs. Workable substitutes:

• One identified case manager who coordinates between separate psychiatric and addiction services
• A psychiatrist comfortable with both disorders (ask explicitly during the first appointment)
• A peer recovery specialist who knows both worlds
• Use of long-acting injectable antipsychotics to maintain stability across substance use lapses
• Active engagement with community resources: NAMI's family support groups, AA/NA, SMART Recovery, recovery community organisations

The role of medication

Integrated programs don't ignore medication — they make heavy use of it. Specific medication strategies that help in dual diagnosis:

• Long-acting injectable antipsychotics for medication adherence during active substance use
• Clozapine for treatment-resistant schizophrenia, with evidence of reduced substance use as a secondary benefit
• Naltrexone, acamprosate, or disulfiram for alcohol use disorder
• Buprenorphine, methadone, or extended-release naltrexone for opioid use disorder
• Varenicline, NRT, or bupropion for tobacco use disorder

Family role

Family members in dual-diagnosis treatment do better when they have their own support. The CRAFT approach is particularly effective for families of people with dual diagnosis. NAMI Family-to-Family also covers co-occurring substance use. Family burnout is a real risk; protect against it by sharing the load and getting your own support.

The bigger picture

Dual diagnosis is the rule, not the exception, in schizophrenia. Treating it well requires integrated care, long timelines, evidence-based medication for both conditions, and a clinical relationship that doesn't end when someone has a setback. When the model is implemented well, outcomes are dramatically better than the historical alternative of bouncing between siloed services. If you or your loved one is being asked to "get sober first" before getting psychiatric help — or vice versa — the system is failing you, and a different program is worth seeking.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.